Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Research

Molecular genetic diagnosis of Glanzmann syndrome in Iranian population; reporting novel and recurrent mutations

Authors: F. Zafarghandi Motlagh, M. S. Fallah, H. Bagherian, T. Shirzadeh, S. Ghasri, S. Dabbagh, M. Jamali, Z. Salehi, M. Abiri, S. Zeinali

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

Glanzmann thrombasthenia (GT) is a rare autosomal recessive abnormality of platelet aggregation with quantitative and/or qualitative abnormality of αIIbβ3 integrin. The αIIbβ3 is a platelet fibrinogen receptor, which is required for platelet aggregation, firm adhesion, and also spreading.
The disease is more prevalent in the populations with a higher rate of consanguineous marriages as in some Middle Eastern populations including Iraq, Jordan, and Iran. Different types of mutations in ITGA2B and ITGB3 genes have been previously reported to cause the disease.

Result

In this study, 16 patients with the clinical diagnosis of GT were studied. Direct sequencing of the exons and exon-intron boundaries of the above genes revealed mutations in 14 patients (detection rate: 87.5%). Briefly, out of fifteen types of identified mutations, 14 were novel. Seven mutations in the ITGB3 gene included 4 missense [c.2T > C, c.155 G > T, c. 538 G > A, c.1990 G > T], one nonsense mutation [c.1303 G > T], a small deletion [c.1656_1658delCTC] and a deletion of one nucleotide [c.401delA]. Mutations in the ITGA2B were 8 different mutations consisting 2 missense [c.286 T > A, c.842 C > T], 2 deletions [c.1899 del T, c.189-319_236del], an insertion [c.1071_1072insG] and one splice site mutations [c.409–3 C > G], one synonymous mutation that might alter the normal splicing process [c.1392 A > G] and a nonsense mutation [c.1555 C > T].
The causative mutation in 2 patients remained unknown. Using long-range PCR and sequencing, we found a rather large deletion. The break point of this deletion covers 319 nt from the last part of the first intron and 48 nt from the beginning of the second exon of ITGA2B gene. The deletion was also detected in two unrelated patients with the same ethnicity. In addition, in silico analyses of novel mutations were performed.

Conclusion

There was no recurrent mutation in the studied population. This may be due to either small sample size or the heterogeneity of the studied population.
Literature
1.
go back to reference Poon MC, D’Oiron R, Von Depka M, Khair K, Negrier C, Karafoulidou A, Huth-Kuehne A, Morfini M. International data collection on recombinant factor V, congenital platelet disorders study G: prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost. 2004;2:1096–103.CrossRef Poon MC, D’Oiron R, Von Depka M, Khair K, Negrier C, Karafoulidou A, Huth-Kuehne A, Morfini M. International data collection on recombinant factor V, congenital platelet disorders study G: prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost. 2004;2:1096–103.CrossRef
2.
go back to reference Handin RI. Inherited platelet disorders. Hematology Am Soc Hematol Educ Program. 2005;1:396–402. Handin RI. Inherited platelet disorders. Hematology Am Soc Hematol Educ Program. 2005;1:396–402.
3.
go back to reference Pillitteri D, Pilgrimm AK, Kirchmaier CM. Novel mutations in the GPIIb and GPIIIa genes in Glanzmann Thrombasthenia. Transfus Med Hemother. 2010;37(5):268–77.CrossRef Pillitteri D, Pilgrimm AK, Kirchmaier CM. Novel mutations in the GPIIb and GPIIIa genes in Glanzmann Thrombasthenia. Transfus Med Hemother. 2010;37(5):268–77.CrossRef
4.
go back to reference Rosenberg N, Hauschner H, Peretz H, Mor-Cohen R, Landau M, Shenkman B, Kenet G, Coller BS, Awidi AA, Seligsohn U. A 13-bp deletion in alpha (IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia. J Thromb Haemost. 2005;3:2764–72.CrossRef Rosenberg N, Hauschner H, Peretz H, Mor-Cohen R, Landau M, Shenkman B, Kenet G, Coller BS, Awidi AA, Seligsohn U. A 13-bp deletion in alpha (IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia. J Thromb Haemost. 2005;3:2764–72.CrossRef
5.
go back to reference Wilcox DA, Wautier JL, Pidard D, Newman PJ. A single amino acid substitution flanking the fourth calcium binding domain of alpha IIb prevents maturation of the alpha IIb beta 3 integrin complex. J Biol Chem. 1994;269:4450–7.PubMed Wilcox DA, Wautier JL, Pidard D, Newman PJ. A single amino acid substitution flanking the fourth calcium binding domain of alpha IIb prevents maturation of the alpha IIb beta 3 integrin complex. J Biol Chem. 1994;269:4450–7.PubMed
6.
go back to reference Carl Maximilian Kirchmaier DP. Diagnosis and Management of Inherited Platelet Disorders. Transfus Med Hemother. 2010;37(5):237–46.PubMedPubMedCentral Carl Maximilian Kirchmaier DP. Diagnosis and Management of Inherited Platelet Disorders. Transfus Med Hemother. 2010;37(5):237–46.PubMedPubMedCentral
7.
go back to reference George JN, Caen JP, Nurden AT. Glanzmann’s thrombasthenia: the spectrum of clinical disease. Blood. 1990;75:1383–95.PubMed George JN, Caen JP, Nurden AT. Glanzmann’s thrombasthenia: the spectrum of clinical disease. Blood. 1990;75:1383–95.PubMed
8.
go back to reference Bellucci S, Caen J. Molecular basis of Glanzmann’s Thrombasthenia and current strategies in treatment. Blood Rev. 2002;16:193–202.CrossRef Bellucci S, Caen J. Molecular basis of Glanzmann’s Thrombasthenia and current strategies in treatment. Blood Rev. 2002;16:193–202.CrossRef
9.
go back to reference Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 1988;71:831–43.PubMed Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 1988;71:831–43.PubMed
10.
go back to reference Miller SADD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.CrossRef Miller SADD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.CrossRef
11.
go back to reference den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, Roux AF, Smith T, Antonarakis SE, Taschner PE. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37(6):564–9.CrossRef den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, Roux AF, Smith T, Antonarakis SE, Taschner PE. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37(6):564–9.CrossRef
12.
go back to reference Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 2010;7:575–6.CrossRef Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 2010;7:575–6.CrossRef
13.
go back to reference Saadat M, Ansari-Lari M, Farhud D. Short report consanguineous marriage in Iran. Ann Hum Biol. 2004;31:263–9.CrossRef Saadat M, Ansari-Lari M, Farhud D. Short report consanguineous marriage in Iran. Ann Hum Biol. 2004;31:263–9.CrossRef
14.
go back to reference Kazemi A, Abolghasemi H, Kazemzadeh S, Vahidi R, Faranoush M, Farsinejad A, Ala F. Molecular characterization of Glanzmann’s thrombasthenia in Iran: identification of three novel mutations. Blood Coagul Fibrinolysis. 2017;28:681–6.CrossRef Kazemi A, Abolghasemi H, Kazemzadeh S, Vahidi R, Faranoush M, Farsinejad A, Ala F. Molecular characterization of Glanzmann’s thrombasthenia in Iran: identification of three novel mutations. Blood Coagul Fibrinolysis. 2017;28:681–6.CrossRef
15.
go back to reference Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248–9.CrossRef Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248–9.CrossRef
16.
go back to reference Venselaar H, te Beek TA, Kuipers RK, Hekkelman ML, Vriend G. Protein structure analysis of mutations causing inheritable diseases. An e-science approach with life scientist friendly interfaces. BMC Bioinf. 2010;11:548.CrossRef Venselaar H, te Beek TA, Kuipers RK, Hekkelman ML, Vriend G. Protein structure analysis of mutations causing inheritable diseases. An e-science approach with life scientist friendly interfaces. BMC Bioinf. 2010;11:548.CrossRef
17.
go back to reference Desmet F-O, Hamroun D, Lalande M, Collod-Béroud G, Claustres M, Béroud C. Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009;37:e67.CrossRef Desmet F-O, Hamroun D, Lalande M, Collod-Béroud G, Claustres M, Béroud C. Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009;37:e67.CrossRef
Metadata
Title
Molecular genetic diagnosis of Glanzmann syndrome in Iranian population; reporting novel and recurrent mutations
Authors
F. Zafarghandi Motlagh
M. S. Fallah
H. Bagherian
T. Shirzadeh
S. Ghasri
S. Dabbagh
M. Jamali
Z. Salehi
M. Abiri
S. Zeinali
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-019-1042-4

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue